Roy Herbst, MD, PhD, FACP, FASCO; Yale Cancer Center 5Live #ASCO20
4:24
Key insights on Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.
Key insights on Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.
Non Small Cell Lung Cancer Similar Videos
-
Vivek Subbiah, MD The University of Texas MD Anderson Cancer Center 5Live #ASCO20
6:47
Key Insights on Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) patients on the LIBRETTO-001 trial.
-
Q&A and Panel Discussion
6:40
-
David Carbone, MD, PhD, FASCO; The Ohio State University Comprehensive Cancer Center; 5Live; #IASLC21
6:56